Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LongeveronLGVN +1.40%45 PS Ratio is 10.02 as of Jul. 19, 2026, which is 53% below its 10-year median of 21.30. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 931 Biotechnology companies, Longeveron ranks worse than 51.99% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Longeveron's share price is $0.611.
Longeveron's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06. Hence, Longeveron's PS Ratio for today is 10.02.
The historical rank and industry rank for Longeveron's PS Ratio or its related term are showing as below:
LGVN'
s PS Ratio Range Over the Past 10 Years
Min: 2.39 Med: 21.3 Max: 237.2
Current: 10.02
During the past 8 years, Longeveron's highest PS Ratio was 237.20. The lowest was 2.39. And the median was 21.30.
LGVN's PS Ratio is ranked worse than 51.99% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs LGVN: 10.02
Longeveron Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Longeveron was -68.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -51.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -48.20% per year.
During the past 8 years, Longeveron's highest 3-Year average Revenue per Share Growth Rate was -19.90% per year. The lowest was -54.00% per year. And the median was -45.10% per year.
Back to Basics: PS Ratio
Longeveron (NAS:LGVN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Longeveron PS Ratio Related Terms
Longeveron PS Ratio Historical Data
* Premium members only.
The historical data trend for Longeveron's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Longeveron's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longeveron PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longeveron's PS Ratio distribution charts can be found below:
* The bar in red indicates where Longeveron's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Longeveron's Share Price of today is $0.611. Longeveron's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Longeveron (LGVN) has a PS Ratio of 10.02 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Longeveron and its competitors. This is 53% below median its historical median of 21.30. Over the past decade, Longeveron's PS Ratio has ranged from 2.39 to 237.20. According to the industry distribution chart, Longeveron ranks #484 out of 931 companies in the Biotechnology industry, placing it in the top 52%.
Is Longeveron's PS Ratio too high?
Longeveron's current PS Ratio of 10.02 is 53% below median its 10-year median of 21.30. Over the past 10 years, this metric has ranged from a low of 2.39 to a high of 237.20. The Biotechnology industry median PS Ratio is 9.32. Longeveron's value of 10.02 is 7.5% above this industry median. Based on the distribution chart, Longeveron ranks #484 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's PS Ratio compare to MRKR and PLUR?
According to the Biotechnology industry distribution chart, Longeveron ranks #484 out of 931 companies for PS Ratio. This places Longeveron in the lower half of its industry. The industry median PS Ratio is 9.32. Longeveron's value of 10.02 is 7.5% above this benchmark. Historically, Longeveron's own PS Ratio has ranged from 2.39 to 237.20 over the past decade. While the company's 10-year median is 21.30 vs. the industry median of 9.32, Longeveron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longeveron's current PS Ratio of 10.02 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Longeveron and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longeveron's current PS Ratio is 10.02, which is 53% below median its own 10-year median of 21.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current PS Ratio is 10.02, which is 53% below median its 10-year median of 21.30 and 7.5% above the Biotechnology industry median of 9.32. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Longeveron (LGVN), the current PS Ratio is 10.02 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longeveron (LGVN) Overvalued in 2026?
Based on GuruFocus' analysis, Longeveron stock appears to be overvalued.
The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38.
GuruFocus considers Longeveron to be Significantly Overvalued.
Key valuation signals for LGVN:
PS Ratio: 10.02 (53% below median its 10-year median of 21.30)
GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
Industry Position: 7.5% above the Biotechnology median (#484 of 931)
No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score
Get the complete analysis for LGVN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LGVN has been successfully added to your 
